| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | NanoViricides, Inc.: A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox | 266 | ACCESSWIRE | NV-387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC)... ► Artikel lesen | |
| Di | NanoViricides, TC BioPharm, Holdco Nuvo among healthcare movers | 7 | Seeking Alpha | ||
| Mo | NanoViricides, Outset Medical, EyePoint Pharmaceuticals among healthcare movers | 6 | Seeking Alpha | ||
| Mo | NanoViricides, Inc.: A Novel Broad-Spectrum Antiviral with Activity Against Influenza A | 640 | ACCESSWIRE | NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides SHELTON, CT / ACCESSWIRE / May 6, 2024 / NanoViricides, Inc. (NYSE American:NNVC)... ► Artikel lesen | |
| 30.04. | NanoViricides, Inc.: NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon | 673 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of... ► Artikel lesen | |
| 05.04. | NANOVIRICIDES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.02. | NANOVIRICIDES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.02. | NanoViricides GAAP EPS of -$0.18 | 1 | Seeking Alpha | ||
| 15.02. | NanoViricides, Inc.: NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon | 961 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly... ► Artikel lesen | |
| 14.02. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 01.02. | NanoViricides, Inc.: Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics | 814 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
| 29.01. | NanoViricides reports positive safety results for COVID drug candidate | 1 | Seeking Alpha | ||
| 29.01. | NanoViricides, Inc.: Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found | 588 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
| 19.01. | NANOVIRICIDES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.01. | NanoViricides, Inc. (NNVC) To Unveil Cutting-Edge Antiviral Breakthroughs At Biotech Showcase 2024 | 2 | Benzinga.com | ||
| 04.01. | NanoViricides, Inc.: NanoViricides to Present at the Biotech Showcase in San Fransisco | 761 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
| 28.11.23 | NanoViricides, Inc.: The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part, Reports NanoViricides | 923 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines... ► Artikel lesen | |
| 15.11.23 | NanoViricides, Inc.: NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications | 1.069 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending... ► Artikel lesen | |
| 14.11.23 | NanoViricides, Inc.: Broad-Spectrum Antiviral NV-387 in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development | 609 | ACCESSWIRE | SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 2.926 |
| NEL | 2.398 |
| MERCEDES-BENZ | 2.354 |
| SIEMENS ENERGY | 2.243 |
| BAYER | 1.900 |
| TUI | 1.820 |
| PLUG POWER | 1.810 |
| ALLIANZ | 1.659 |
| PALANTIR TECHNOLOGIES | 1.645 |
| BYD | 1.334 |
| NVIDIA | 1.309 |
| DEUTSCHE BANK | 1.275 |
| DEUTSCHE LUFTHANSA | 1.210 |
| INFINEON | 1.032 |
| RWE | 1.015 |
| VARTA | 1.000 |
| PUMA | 998 |
| VOLKSWAGEN | 955 |
| RENK GROUP | 905 |
| TESLA | 894 |
| SUPER MICRO COMPUTER | 889 |
| RHEINMETALL | 887 |
| BORUSSIA DORTMUND | 884 |
| AIXTRON SE | 878 |
| SMA SOLAR | 873 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
